Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy

Xin Li,1 Xiaoqian Jia,2 Hu Niu2 1Department of Breast and Thyroid Surgery, Heze Municipal Hospital, Heze, Shandong, China; 2Department of General Surgery 2, The Fourth People’s Hospital of Jinan, Jinan, Shandong, China Background: Multidrug resistance is responsible for the poor outcome...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li X, Jia X, Niu H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	β-lapachone doxorubicin nanostructured lipid carriers multidrug resistance breast cancer Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c729af607cab47ebb3abc5a25878ee1d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c729af607cab47ebb3abc5a25878ee1d
record_format	dspace
spelling	oai:doaj.org-article:c729af607cab47ebb3abc5a25878ee1d2021-12-02T00:20:35ZNanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy1178-2013https://doaj.org/article/c729af607cab47ebb3abc5a25878ee1d2018-07-01T00:00:00Zhttps://www.dovepress.com/nanostructured-lipid-carriers-co-delivering-lapachone-and-doxorubicin--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Xin Li,1 Xiaoqian Jia,2 Hu Niu2 1Department of Breast and Thyroid Surgery, Heze Municipal Hospital, Heze, Shandong, China; 2Department of General Surgery 2, The Fourth People’s Hospital of Jinan, Jinan, Shandong, China Background: Multidrug resistance is responsible for the poor outcome in breast cancer therapy. Lapa is a novel therapeutic agent that generates ROS through the catalysis of the NAD(P)H:quinone oxidoreductase-1 (NQO1) enzyme which significantly facilitate the intracellular accumulation of the co-delivered DOX to overcome MDR in cancer cells. Purpose: Herein, in our study, nanostructured lipid carrier (NLC) co-delivering β-lapachone (Lapa) and doxorubicin (DOX) was developed (LDNLC) with the aim to overcome the multidrug resistance (MDR) in breast cancer therapy. Patients and methods: Lapa and DOX were loaded into NLC to prepare LDNLC using melted ultrasonic dispersion method. Results: The well designed LDNLC was nanoscaled particles that exhibited preferable stability in physiological environment. In vitro cell experiments on MCF-7 ADR cells showed increased DOX retention as compared to DOX mono-delivery NLC (DNLC). In vivo anti-cancer assays on MCF-7 ADR tumor bearing mice model also revealed significantly enhanced efficacy of LDNLC than mono-delivery NLCs (DNLC and LNLC). Conclusion: LDNLC might be a promising platform for effective breast cancer therapy. Keywords: β-lapachone, doxorubicin, nanostructured lipid carriers, multidrug resistance, breast cancerLi XJia XNiu HDove Medical Pressarticleβ-lapachonedoxorubicinnanostructured lipid carriersmultidrug resistancebreast cancerMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 4107-4119 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	β-lapachone doxorubicin nanostructured lipid carriers multidrug resistance breast cancer Medicine (General) R5-920
spellingShingle	β-lapachone doxorubicin nanostructured lipid carriers multidrug resistance breast cancer Medicine (General) R5-920 Li X Jia X Niu H Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy
description	Xin Li,1 Xiaoqian Jia,2 Hu Niu2 1Department of Breast and Thyroid Surgery, Heze Municipal Hospital, Heze, Shandong, China; 2Department of General Surgery 2, The Fourth People’s Hospital of Jinan, Jinan, Shandong, China Background: Multidrug resistance is responsible for the poor outcome in breast cancer therapy. Lapa is a novel therapeutic agent that generates ROS through the catalysis of the NAD(P)H:quinone oxidoreductase-1 (NQO1) enzyme which significantly facilitate the intracellular accumulation of the co-delivered DOX to overcome MDR in cancer cells. Purpose: Herein, in our study, nanostructured lipid carrier (NLC) co-delivering β-lapachone (Lapa) and doxorubicin (DOX) was developed (LDNLC) with the aim to overcome the multidrug resistance (MDR) in breast cancer therapy. Patients and methods: Lapa and DOX were loaded into NLC to prepare LDNLC using melted ultrasonic dispersion method. Results: The well designed LDNLC was nanoscaled particles that exhibited preferable stability in physiological environment. In vitro cell experiments on MCF-7 ADR cells showed increased DOX retention as compared to DOX mono-delivery NLC (DNLC). In vivo anti-cancer assays on MCF-7 ADR tumor bearing mice model also revealed significantly enhanced efficacy of LDNLC than mono-delivery NLCs (DNLC and LNLC). Conclusion: LDNLC might be a promising platform for effective breast cancer therapy. Keywords: β-lapachone, doxorubicin, nanostructured lipid carriers, multidrug resistance, breast cancer
format	article
author	Li X Jia X Niu H
author_facet	Li X Jia X Niu H
author_sort	Li X
title	Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy
title_short	Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy
title_full	Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy
title_fullStr	Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy
title_full_unstemmed	Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy
title_sort	nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/c729af607cab47ebb3abc5a25878ee1d
work_keys_str_mv	AT lix nanostructuredlipidcarrierscodeliveringlapachoneanddoxorubicinforovercomingmultidrugresistanceinbreastcancertherapy AT jiax nanostructuredlipidcarrierscodeliveringlapachoneanddoxorubicinforovercomingmultidrugresistanceinbreastcancertherapy AT niuh nanostructuredlipidcarrierscodeliveringlapachoneanddoxorubicinforovercomingmultidrugresistanceinbreastcancertherapy
_version_	1718403827602817024

Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy

Ejemplares similares